supemtek solution
sanofi pasteur limited - hémagglutinine recombinée -souche a (h1n1); hémagglutinine recombinée -souche a (h3n2); hémagglutinine recombinée -souche b (victoria); hémagglutinine recombinée -souche b (yamagata) - solution - 45mcg; 45mcg; 45mcg; 45mcg - hémagglutinine recombinée -souche a (h1n1) 45mcg; hémagglutinine recombinée -souche a (h3n2) 45mcg; hémagglutinine recombinée -souche b (victoria) 45mcg; hémagglutinine recombinée -souche b (yamagata) 45mcg - vaccines
vaxigriptetra suspension pour injection dans une seringue pré-remplie
sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/4897/2022 (h1n1)pdm09-like: reassortant virus ivr-238 derived from a/victoria/4897/2022), haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021), haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) - suspension pour injection dans une seringue pré-remplie - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/4897/2022 (h1n1)pdm09-like: reassortant virus ivr-238 derived from a/victoria/4897/2022) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021) 15 µg, haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013-like: b/phuket/3073/2013, wilde type (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - immunisation active contre l'influenza, dès le 6ème mois - les vaccins
efluelda 0.7 ml suspension injectable en seringue préremplie
sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/4897/2022 (h1n1)-like: reassortant virus ivr-238 derived from a/victoria/4897/2022), haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus san-010 derived from a/darwin/9/2021), haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: derived from b/michigan/01/2021 (victoria lineage)(wild type)) - suspension injectable en seringue préremplie - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/4897/2022 (h1n1)-like: reassortant virus ivr-238 derived from a/victoria/4897/2022) 60 µg, haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus san-010 derived from a/darwin/9/2021) 60 µg, haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: derived from b/michigan/01/2021 (victoria lineage)(wild type)) 60 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage) (wild type)) 60 µg, natrii chloridum, dinatrii phosphas, natrii dihydrogenophosphas anhydricus, octoxinolum-9, aqua ad iniectabile q.s. ad suspensionem pro 0.7 ml corresp. natrium 2.72 mg. - immunisation active contre l'influenza, dès 65 ans - les vaccins
afluria tetra suspension
seqirus pty ltd - hémagglutinine-souche a (h1n1); hémagglutinine-souche a (h3n2); hémagglutinine-souche b (victoria); hémagglutinine-souche b (yamagata) - suspension - 15mcg; 15mcg; 15mcg; 15mcg - hémagglutinine-souche a (h1n1) 15mcg; hémagglutinine-souche a (h3n2) 15mcg; hémagglutinine-souche b (victoria) 15mcg; hémagglutinine-souche b (yamagata) 15mcg - vaccines
afluria tetra suspension
seqirus pty ltd - hémagglutinine-souche a (h1n1); hémagglutinine-souche a (h3n2); hémagglutinine-souche b (victoria); hémagglutinine-souche b (yamagata) - suspension - 15mcg; 15mcg; 15mcg; 15mcg - hémagglutinine-souche a (h1n1) 15mcg; hémagglutinine-souche a (h3n2) 15mcg; hémagglutinine-souche b (victoria) 15mcg; hémagglutinine-souche b (yamagata) 15mcg - vaccines
fluzone high-dose quadrivalent suspension
sanofi pasteur limited - hémagglutinine-souche a (h1n1); hémagglutinine-souche a (h3n2); hémagglutinine-souche b (victoria); hémagglutinine-souche b (yamagata) - suspension - 60mcg; 60mcg; 60mcg; 60mcg - hémagglutinine-souche a (h1n1) 60mcg; hémagglutinine-souche a (h3n2) 60mcg; hémagglutinine-souche b (victoria) 60mcg; hémagglutinine-souche b (yamagata) 60mcg - vaccines
flucelvax quad suspension
seqirus uk limited - hémagglutinine-souche a (h1n1); hémagglutinine-souche a (h3n2); hémagglutinine-souche b (victoria); hémagglutinine-souche b (yamagata) - suspension - 15mcg; 15mcg; 15mcg; 15mcg - hémagglutinine-souche a (h1n1) 15mcg; hémagglutinine-souche a (h3n2) 15mcg; hémagglutinine-souche b (victoria) 15mcg; hémagglutinine-souche b (yamagata) 15mcg - vaccines
flucelvax quad suspension
seqirus uk limited - hémagglutinine-souche b (victoria); hémagglutinine-souche b (yamagata); hémagglutinine-souche a (h3n2); hémagglutinine-souche a (h1n1) - suspension - 15mcg; 15mcg; 15mcg; 15mcg - hémagglutinine-souche b (victoria) 15mcg; hémagglutinine-souche b (yamagata) 15mcg; hémagglutinine-souche a (h3n2) 15mcg; hémagglutinine-souche a (h1n1) 15mcg - vaccines
fluenz tetra nasenspray, suspension
astrazeneca ag - virus influenzae a (h1n1) vivus attenuatum (virus-stamm a/victoria/4897/2022 (h1n1)pdm09-like strain (a/norway/31694/2022, medi 369815)), virus influenzae a (h3n2) vivus attenuatum (virus-stamm a/darwin/9/2021 (h3n2)-like (a/norway/16606/2021 (medi 355293)), virus influenzae b vivus attenuatum (virus-stamm b/austria/1359417/2021-like: b/austria/1359417/2021 (medi 355293, victoria lineage)) - nasenspray, suspension - virus influenzae a (h1n1) vivus attenuatum (virus-stamm a/victoria/4897/2022 (h1n1)pdm09-like strain (a/norway/31694/2022, medi 369815)) 70 mio. ffu, virus influenzae a (h3n2) vivus attenuatum (virus-stamm a/darwin/9/2021 (h3n2)-like (a/norway/16606/2021 (medi 355293)) 70 mio. ffu, virus influenzae b vivus attenuatum (virus-stamm b/austria/1359417/2021-like: b/austria/1359417/2021 (medi 355293, victoria lineage)) 70 mio. ffu, virus influenzae b vivus attenuatum (virus-stamm b/phuket/3073/2013-like: b/phuket/3073/2013 (medi 306444, yamagata lineage)) 70 mio. ffu, saccharum, dikalii phosphas anhydricus, kalii dihydrogenophosphas, gelatina hydrolysata, arginini hydrochloridum, natrii hydrogenoglutamas monohydricus, aqua ad iniectabile q.s. ad suspensionem pro 0.2 ml. - aktive immunisierung gegen influenza für kinder und jugendliche im alter von 2-18 jahren - les vaccins
fluenz tetra
astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - grippe humaine - les vaccins contre la grippe, l'influenza, virus vivant atténué - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. l'utilisation de fluenz tetra doit être basée sur des recommandations officielles.